L
Lovenox
A $120 million settlement was reached for those who indirectly purchased Lovenox or its generic equivalent enoxaparin.
ClosedUnited States-wideClaim status: Claim window closedPayout: Closed settlementNo longer claimable
About this settlement
Class action settlement for consumers who indirectly purchased Lovenox or enoxaparin due to alleged price-fixing.
This settlement resolves claims related to alleged price-fixing of the blood thinner Lovenox and its generic equivalent enoxaparin. Eligible claimants who indirectly purchased these drugs may have received compensation from the $120 million fund.
Who qualifies
- Individuals who indirectly purchased Lovenox or enoxaparin.
- Purchases related to the price-fixing period covered by the settlement.
Closed settlement
Claim status: Claim window closed